MCID: GST037
MIFTS: 54

Gastroparesis malady

Categories: Gastrointestinal diseases

Aliases & Classifications for Gastroparesis

Aliases & Descriptions for Gastroparesis:

Name: Gastroparesis 12 52 42 14 69
Gastroparesis Syndrome 12 29
Gastroparalysis 12
Gastric Atonia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:11914
ICD10 33 K31.84
ICD9CM 35 536.3
MeSH 42 D018589
NCIt 47 C80512
UMLS 69 C0152020

Summaries for Gastroparesis

MalaCards based summary : Gastroparesis, also known as gastroparesis syndrome, is related to autoimmune gastrointestinal dysmotility and brittle diabetes, and has symptoms including hemiplegia, ophthalmoplegia and paresis. An important gene associated with Gastroparesis is MLN (Motilin), and among its related pathways/superpathways are Peptide ligand-binding receptors and Dopamine-DARPP32 Feedback onto cAMP Pathway. The drugs Domperidone and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include small intestine, lung and testes, and related phenotypes are Decreased viability and behavior/neurological

Wikipedia : 71 Gastroparesis (GP) (gastro- from Ancient Greek γαστήρ gaster, \"stomach\" and πάρεσις... more...

Related Diseases for Gastroparesis

Diseases related to Gastroparesis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 106)
id Related Disease Score Top Affiliating Genes
1 autoimmune gastrointestinal dysmotility 10.8
2 brittle diabetes 10.8
3 tacrolimus dose selection 10.2 ABCB1 CYP2D6
4 sphenoorbital meningioma 10.2 DRD2 DRD3
5 hidrocystoma 10.1 MLN MLNR
6 intracranial aneurysm 10.1 DRD2 DRD3
7 dyspepsia 10.1
8 pyromania 10.1 DRD2 DRD3
9 gastric duplication cysts 10.1 GAST GHRL
10 chorea gravidarum 10.1 CYP2D6 DRD2
11 teratoma with malignant transformation 10.1 CYP2D6 DRD2 DRD3
12 mucinous adenocarcinoma 10.0 CYP2D6 DRD2 DRD3
13 nutritional optic neuropathy 10.0 GAST GHRL MLN
14 hypereosinophilic syndrome 10.0 CYP2D6 DRD2 DRD3
15 pellagra 10.0 ABCB1 CCK
16 hemochromatosis, type 2a 10.0 CYP2D6 DRD2 DRD3
17 hepatitis b reinfection following liver transplantation 10.0 CYP2D6 GAST HTR3A
18 acute contagious conjunctivitis 10.0 CCK DRD2
19 cytomegalic congenital adrenal hypoplasia 10.0 DRD2 DRD3 HTR3A
20 postpoliomyelitis syndrome 10.0 CCK GAST
21 acinar cell cystadenocarcinoma 10.0 GAST GHRL
22 breast malignant eccrine spiradenoma 10.0 CCK GAST
23 myocardial stunning 10.0 CCK GAST MLN
24 deafness, autosomal recessive 1a 10.0 CCK GAST
25 tricuspid valve stenosis 10.0 CCK GAST MLN
26 microcephaly 13, primary, autosomal recessive 9.9 DRD2 DRD3 HTR3A
27 adult brain stem glioma 9.9 CCK GAST MLN
28 c8 deficiency, type ii 9.9 DRD2 DRD3
29 gemistocytic astrocytoma 9.9 CCK GAST
30 neuropathy 9.9
31 ornithosis 9.9 CCK DRD2 HTR3A
32 deafness, autosomal recessive 20 9.9 CCK HTR3A MLN
33 tuberculous peritonitis 9.9 CCK HTR3A MLN
34 retinoblastoma 9.9 CYP2D6 DRD2 DRD3 HTR3A
35 obesity 9.9
36 pancreatitis 9.9
37 neuronitis 9.9
38 constipation 9.8
39 cholesteatoma 9.8 CCK DRD2 GHRL
40 hyperornithinemia-hyperammonemia-homocitrullinemia syndrome 9.8 CCK GAST GHRL
41 hepatitis d 9.8 CCK CYP2D6 DRD2 HTR3A
42 lung cancer 9.8
43 esophagitis 9.8
44 autonomic dysfunction 9.8
45 dysphagia 9.8
46 personality disorder 9.7 CCK CYP2D6 DRD2 DRD3
47 mandibular cancer 9.7 CCK GHRL HTR3A
48 chagas disease 9.7 CCK GHRL HTR3A
49 typhoid fever 9.7 ABCB1 CCK GAST HTR3A
50 childhood malignant hemangiopericytoma 9.7 CCK GAST GHRL MLN

Graphical network of the top 20 diseases related to Gastroparesis:



Diseases related to Gastroparesis

Symptoms & Phenotypes for Gastroparesis

UMLS symptoms related to Gastroparesis:


hemiplegia, ophthalmoplegia, paresis, signs and symptoms, digestive, lassitude, persistent vomiting

GenomeRNAi Phenotypes related to Gastroparesis according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.17 GHSR HTR3A MLN
2 Decreased viability GR00381-A-2 9.17 GHSR
3 Decreased viability GR00381-A-3 9.17 GHSR HTR3A MLN

MGI Mouse Phenotypes related to Gastroparesis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.86 ABCB1 CCK DRD2 DRD3 GHRL GHSR
2 adipose tissue MP:0005375 9.72 DRD2 DRD3 GHRL GHSR NOS1
3 digestive/alimentary MP:0005381 9.7 ABCB1 DRD2 DRD3 GAST GHRL GHSR
4 endocrine/exocrine gland MP:0005379 9.5 ABCB1 CCK DRD2 GAST GHRL HTR3A
5 homeostasis/metabolism MP:0005376 9.28 DRD3 GAST GHRL GHSR HTR3A NOS1

Drugs & Therapeutics for Gastroparesis

Drugs for Gastroparesis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 182)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Domperidone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 57808-66-9 3151
2
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
3
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
4
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
5
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
6
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2 50-23-7 5754 657311
7
Tadalafil Approved, Investigational Phase 4,Phase 2 171596-29-5 110635
8
Ticagrelor Approved Phase 4 274693-27-5 9871419
9
Haloperidol Approved Phase 4 52-86-8 3559
10
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
11
Butyric Acid Experimental Phase 4,Phase 2 107-92-6 264
12
decanoic acid Experimental Phase 4 334-48-5 2969
13 Anticoagulants Phase 4
14 Antiemetics Phase 4,Phase 3,Phase 2
15 Autonomic Agents Phase 4,Phase 3,Phase 2
16 Calcium, Dietary Phase 4
17 Chelating Agents Phase 4,Phase 3
18 Dopamine Agents Phase 4,Phase 3,Phase 2
19 Dopamine Antagonists Phase 4,Phase 3,Phase 2
20 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
21 mosapride Phase 4 112885-41-3
22 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
24
Serotonin Phase 4,Phase 3,Phase 2,Phase 1 50-67-9 5202
25 Serotonin Agents Phase 4,Phase 3,Phase 2
26 glucagon Phase 4
27 Glucagon-Like Peptide 1 Phase 4
28 Antacids Phase 4,Phase 1
29 Anti-Ulcer Agents Phase 4,Phase 1
30
Proton pump inhibitors Phase 4
31 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
32 Cortisol succinate Phase 4,Phase 2
33 Hydrocortisone 17-butyrate 21-propionate Phase 4,Phase 2
34 Hydrocortisone acetate Phase 4,Phase 2
35 Hydrocortisone-17-butyrate Phase 4,Phase 2
36 Central Nervous System Depressants Phase 4,Phase 2
37 Psychotropic Drugs Phase 4,Phase 3,Phase 2
38 Hormone Antagonists Phase 4,Phase 2,Phase 1
39 Hormones Phase 4,Phase 2,Phase 1
40 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 1
41 Hypoglycemic Agents Phase 4,Phase 2,Phase 3,Phase 1
42 Incretins Phase 4,Phase 2,Phase 1
43 Phosphodiesterase 5 Inhibitors Phase 4,Phase 2
44 Phosphodiesterase Inhibitors Phase 4,Phase 2
45 Vasodilator Agents Phase 4,Phase 2
46 Analgesics Phase 4,Phase 2
47 Analgesics, Non-Narcotic Phase 4
48 Antipyretics Phase 4
49 Antipsychotic Agents Phase 4,Phase 2
50 Tranquilizing Agents Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 213)
id Name Status NCT ID Phase
1 Effects and Mechanism of Mosapride Citrate on Diabetic Gastroparesis Unknown status NCT02264587 Phase 4
2 Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2 Unknown status NCT00473733 Phase 4
3 Gastric Functions & Proton Pump Inhibitor( PPI) Study Unknown status NCT00951431 Phase 4
4 Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Gastroparesis Completed NCT00492622 Phase 4
5 Limited Access Protocol for the Use of Oral Cisapride Completed NCT02524496 Phase 4
6 Prucalopride Versus Placebo in Gastroparesis Recruiting NCT02510976 Phase 4
7 Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy Recruiting NCT01642875 Phase 4
8 Impairment of Gastric Emptying During Acute Phase of Myocardial Infarction. Impact on Oral Antiplatelet Treatment Efficacy. The GASTRIM Study. Recruiting NCT02251249 Phase 4
9 Hydrocortisone vs. Pasireotide in Preventing Pancreatic Surgery Complications Recruiting NCT02775227 Phase 4
10 An Efficacy and Safety Study of Cisapride in Patients With Chronic Gastroparesis After Failure of Other Treatment Options Terminated NCT01281540 Phase 4
11 An Efficacy and Safety Study of Cisapride for Improving Symptoms Associated With Gastroparesis in Patients With Diabetes Mellitus Terminated NCT01286090 Phase 4
12 Haloperidol vs Conventional Therapy for Gastroparesis Terminated NCT02057549 Phase 4
13 Effect of Tegaserod on Gastric Emptying in Patients With Diabetic Gastroparesis Terminated NCT00390975 Phase 4
14 Enterra Therapy Gastric Stimulation System Terminated NCT00556166 Phase 4
15 An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects Terminated NCT02793154 Phase 4
16 Gastric vs Jejunal Feeding in Diabetic Gastroparesis Withdrawn NCT00944593 Phase 4
17 Daily Tadalafil and Gastric Emptying Time in Diabetic Gastroparesis Withdrawn NCT01326117 Phase 4
18 Sancuso® for Gastroparesis: An Open Label Study. Unknown status NCT01989221 Phase 3
19 Effect of Electroacupuncture in Diabetic Patients With Gastroparesis Unknown status NCT00227383 Phase 3
20 A Prospective Randomized Controlled Multicenter Trial of Delayed Gastric Emptying (DGE) After Pancreaticoduodenectomy Evaluating by Gastrointestinal Reconstruction Unknown status NCT01460550 Phase 3
21 Nortriptyline for Idiopathic Gastroparesis Completed NCT00765895 Phase 3
22 Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis Completed NCT00432835 Phase 3
23 Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis Completed NCT02025725 Phase 3
24 Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis Completed NCT02025751 Phase 3
25 Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial Completed NCT01149369 Phase 3
26 Using Magnetic Resonance (MR) to Understand the Effect of Erythromycin on Bowel Motility Completed NCT01379183 Phase 2, Phase 3
27 Prucalopride Versus Placebo in Gastroparesis Recruiting NCT02031081 Phase 2, Phase 3
28 Treatment Protocol for the Compassionate Use of Domperidone Recruiting NCT01696734 Phase 3
29 Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomy Recruiting NCT02457156 Phase 3
30 Anti-inflammatory Effect of Peroperative Stimulation of the Vagus Nerve Recruiting NCT02524626 Phase 3
31 Per-oral Endoscopy Pyloromyotomy (G-POEM) in the Treatment of Refractory Diabetic Gastroparesis : Prospective Evaluation of Efficacy Not yet recruiting NCT02927886 Phase 3
32 REinforcement of the Pancreas in distaL pAncreatectomY (REPLAY) Not yet recruiting NCT03030170 Phase 3
33 Acupuncture for Diabetic Gastroparesis Suspended NCT00470795 Phase 3
34 Effects of Pulsatile Insulin Delivery on Diabetic Neuropathy in Patients With Types 1 and 2 Diabetes Mellitus Terminated NCT00228891 Phase 2, Phase 3
35 The Use of Domperidone for Gastroparesis Withdrawn NCT01378884 Phase 3
36 Comparison Study for Bile Reflux and Gastric Stasis in Patients After Distal Gastrectomy Withdrawn NCT00622804 Phase 3
37 Effects of Pulsatile Intravenous Insulin Delivery on Diabetic Neuropathy in pATIENTS (Pts) With Type 1 and Type 2 Diabetes Withdrawn NCT00228904 Phase 2, Phase 3
38 Cannabis for Inflammatory Bowel Disease Unknown status NCT01040910 Phase 1, Phase 2
39 The Use of a Restrictive Fluid Regimen With Hypertonic Saline for Patients Undergoing Pancreaticoduodenectomy Unknown status NCT01428050 Phase 2
40 External Drainage Versus Internal Drainage of Pancreatic Duct With a Stent After Pancreaticoduodenectomy (EDIDPD) Unknown status NCT01634971 Phase 2
41 Acupuncture Treatment for Gastroparesis: a Pilot Study Completed NCT01643577 Phase 1, Phase 2
42 A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis Completed NCT02210000 Phase 2
43 Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Severe Diabetic Gastroparesis Completed NCT00612014 Phase 2
44 Safety and Efficacy of Once-daily Oral Administrations of TZP-102 for Gastroparesis in Patients With Diabetes Mellitus Completed NCT00889486 Phase 2
45 Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP) Completed NCT02289846 Phase 2
46 Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis Completed NCT01718938 Phase 2
47 A Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis Completed NCT02357420 Phase 2
48 Safety and Effectiveness of an Investigational Agent (GM-611) in Patients With Diabetic Gastroparesis Completed NCT00050882 Phase 2
49 Efficacy and Safety of Metoclopramide Nasal Spray Solution in Diabetic Patients With Gastroparesis Completed NCT00845858 Phase 2
50 Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis Completed NCT01452815 Phase 2

Search NIH Clinical Center for Gastroparesis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: gastroparesis

Genetic Tests for Gastroparesis

Genetic tests related to Gastroparesis:

id Genetic test Affiliating Genes
1 Gastroparesis 29

Anatomical Context for Gastroparesis

MalaCards organs/tissues related to Gastroparesis:

39
Small Intestine, Lung, Testes, Heart, Kidney, Pancreas, Liver

Publications for Gastroparesis

Articles related to Gastroparesis:

(show top 50) (show all 630)
id Title Authors Year
1
Gastric peroral endoscopic pyloromyotomy as a salvage therapy for refractory gastroparesis: a case series of different subtypes. ( 28028897 )
2017
2
Exploration of the psychosocial issues associated with gastroparesis: A qualitative investigation. ( 28071866 )
2017
3
Diabetic and idiopathic gastroparesis is associated with loss of CD206-positive macrophages in the gastric antrum. ( 28066953 )
2017
4
Endoscopic Pyloromyotomy for the Treatment of Severe Refractory Diabetic Gastroparesis. ( 28050040 )
2017
5
POEMs for gastroparesis. ( 27986106 )
2017
6
The Long-Term Efficacy and Safety of Pyloroplasty Combined with Gastric Electrical Stimulation Therapy in Gastroparesis. ( 27896652 )
2017
7
Acute Slow Wave Responses to High-Frequency Gastric Electrical Stimulation in Patients With Gastroparesis Defined by High-Resolution Mapping. ( 27284964 )
2016
8
Effect of electroacupuncture on gastric interstitial cells of Cajal in a rat model of diabetic gastroparesis. ( 27284337 )
2016
9
Effects of hemin on heme oxygenase-1, gastric emptying, and symptoms in diabetic gastroparesis. ( 27283929 )
2016
10
Pharmacologic Treatment for Pediatric Gastroparesis: A Review of the Literature. ( 27199619 )
2016
11
Innovative gastric endoscopic muscle biopsy to identify all cell types, including myenteric neurons and interstitial cells of Cajal in patients with idiopathic gastroparesis: a feasibility study (with video). ( 27129395 )
2016
12
Per-oral endoscopic pyloromyotomy and per-oral endoscopic myotomy for coexisting refractory gastroparesis and recurrent achalasia cardia in a single patient. ( 27090287 )
2016
13
Prevalence and risk factors of gastroparesis-related symptoms among patients with type 2 diabetes. ( 27610063 )
2016
14
Autonomic Evaluation of Patients With Gastroparesis and Neurostimulation: Comparisons of Direct/Systemic and Indirect/Cardiac Measures. ( 27785318 )
2016
15
Quantifying the "Slosh Stomach": A Novel Tool for Assessment of Exercise-Associated Gastroparesis Symptoms in Endurance Athletes. ( 27981229 )
2016
16
Early satiety and postprandial fullness in gastroparesis correlate with gastroparesis severity, gastric emptying, and water load testing. ( 27781342 )
2016
17
Randomized clinical trial: a controlled pilot trial of the 5-HT4 receptor agonist revexepride in patients with symptoms suggestive of gastroparesis. ( 27010235 )
2016
18
The impact of gastroparesis on diabetes control: Patient perceptions. ( 27166926 )
2016
19
Safety of treatment for gastroparesis. ( 27031006 )
2016
20
Gastroparesis: Quality of Life and Health Care Utilization. ( 27775961 )
2016
21
Gastroparesis in a patient with Parkinson's disease. ( 27166113 )
2016
22
Gastric per-oral endoscopic myotomy with antropyloromyotomy in the treatment of refractory gastroparesis: clinical experience with follow-up and scintigraphic evaluation (with video). ( 27478028 )
2016
23
Levothyroxine Tablet Malabsorption Associated with Gastroparesis Corrected with Gelatin Capsule Formulation. ( 27293919 )
2016
24
Granisetron Transdermal System for Treatment of Symptoms of Gastroparesis: A Prescription Registry Study. ( 27400689 )
2016
25
Gastric per-oral endoscopic myotomy for refractory gastroparesis: results from the first multicenter study on endoscopic pyloromyotomy (with video). ( 27354102 )
2016
26
Is Gastroparesis Found More Frequently in Patients with Cystic Fibrosis? A Systematic Review. ( 27313953 )
2016
27
Evaluation of gastric blood supply in diabetic patients with gastroparesis by contrast-enhanced ultrasound. ( 27759430 )
2016
28
Twenty-five years of advocacy for patients with gastroparesis: support group therapy and patient reported outcome tool development. ( 27576470 )
2016
29
Depleted interstitial cells of Cajal and fibrosis in the pylorus: Novel features of gastroparesis. ( 26940535 )
2016
30
Yield of Endoscopy in Pediatric Gastroparesis. ( 27741058 )
2016
31
Baseline features and differences in 48 week clinical outcomes in patients with gastroparesis and type 1 vs type 2 diabetes. ( 26946489 )
2016
32
The Management of Gastroparesis Associated Malnutrition. ( 27111029 )
2016
33
Upper Gastrointestinal Tract Motility Disorders in Women, Gastroparesis, and Gastroesophageal Reflux Disease. ( 27261896 )
2016
34
Increased Expression of Pyloric ERI^ Is Associated With Diabetic Gastroparesis in Streptozotocin-Induced Male Diabetic Rats. ( 27785323 )
2016
35
Influence of Musa sapientum L. on pharmacokinetic of metformin in diabetic gastroparesis. ( 27460491 )
2016
36
Effect of endoscopic pyloric therapies for patients with nausea and vomiting and functional obstructive gastroparesis. ( 27460691 )
2016
37
The Association Between Fasting C-peptide and Gastrointestinal Symptoms of Gastroparesis in Type 2 Diabetic Patients. ( 27820956 )
2016
38
Towards a better drug for gastroparesis- the problem with a "moving" target. ( 27215652 )
2016
39
Gastric peroral endoscopic pyloromyotomy (G-POEM) as a salvage therapy for refractory gastroparesis: a case series of different subtypes. ( 27197717 )
2016
40
Systematic review and meta-analysis: Gastric electrical stimulation for gastroparesis. ( 27085627 )
2016
41
Pancreatic Adenocarcinoma Invading the Duodenum and Presenting as Idiopathic Gastroparesis with Nausea and Vomiting. ( 27807571 )
2016
42
Living With Gastroparesis: A Little Hope Goes a Long Way. ( 27068717 )
2016
43
Profound opiate toxicity in gastroparesis following therapeutic dose. ( 27147632 )
2016
44
The Vomiting Patient: Small Bowel Obstruction, Cyclic Vomiting, and Gastroparesis. ( 27133244 )
2016
45
Nausea and vomiting in gastroparesis: similarities and differences in idiopathic and diabetic gastroparesis. ( 27350152 )
2016
46
Functional Dyspepsia and Gastroparesis. ( 27332558 )
2016
47
Immunomodulation for treatment of drug and device refractory gastroparesis. ( 27014566 )
2016
48
Treating an oft-unrecognized and troublesome entity: using gastric electrical stimulation to reduce symptoms of malignancy-associated gastroparesis. ( 27534962 )
2016
49
The rising cost of hospital care for children with gastroparesis: 2004-2013. ( 27226406 )
2016
50
Per-Oral Pyloromyotomy (POP): An Emerging Application of Submucosal Tunneling for the Treatment of Refractory Gastroparesis. ( 27036896 )
2016

Variations for Gastroparesis

Expression for Gastroparesis

Search GEO for disease gene expression data for Gastroparesis.

Pathways for Gastroparesis

GO Terms for Gastroparesis

Cellular components related to Gastroparesis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 8.92 CCK DRD2 GHRL HTR3A

Biological processes related to Gastroparesis according to GeneCards Suite gene sharing:

(show all 40)
id Name GO ID Score Top Affiliating Genes
1 response to ethanol GO:0045471 9.8 DRD2 DRD3 HTR3A
2 negative regulation of protein kinase B signaling GO:0051898 9.68 DRD2 DRD3
3 positive regulation of cytokinesis GO:0032467 9.68 DRD2 DRD3
4 response to morphine GO:0043278 9.68 DRD2 DRD3
5 hormone-mediated signaling pathway GO:0009755 9.67 GHRL GHSR
6 negative regulation of adenylate cyclase activity GO:0007194 9.67 DRD2 DRD3
7 response to amphetamine GO:0001975 9.67 DRD2 DRD3
8 arachidonic acid secretion GO:0050482 9.66 DRD2 DRD3
9 decidualization GO:0046697 9.66 GHRL GHSR
10 response to food GO:0032094 9.65 GAST GHSR
11 regulation of dopamine secretion GO:0014059 9.65 DRD2 DRD3
12 regulation of sodium ion transport GO:0002028 9.65 DRD2 NOS1
13 behavioral response to cocaine GO:0048148 9.64 DRD2 DRD3
14 dopamine receptor signaling pathway GO:0007212 9.64 DRD2 DRD3
15 synaptic transmission, dopaminergic GO:0001963 9.63 DRD2 DRD3
16 response to cocaine GO:0042220 9.63 DRD2 DRD3 HTR3A
17 dopamine metabolic process GO:0042417 9.62 DRD2 DRD3
18 actin polymerization or depolymerization GO:0008154 9.62 GHRL GHSR
19 prepulse inhibition GO:0060134 9.61 DRD2 DRD3
20 positive regulation of renal sodium excretion GO:0035815 9.61 DRD2 DRD3
21 negative regulation of protein secretion GO:0050709 9.6 DRD2 DRD3
22 G-protein coupled receptor internalization GO:0002031 9.59 DRD2 DRD3
23 adult feeding behavior GO:0008343 9.58 GHRL GHSR
24 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.58 DRD2 DRD3
25 positive regulation of growth hormone secretion GO:0060124 9.57 DRD2 GHRL
26 negative regulation of interleukin-1 beta production GO:0032691 9.56 GHRL GHSR
27 growth hormone secretion GO:0030252 9.55 GHRL GHSR
28 regulation of cAMP metabolic process GO:0030814 9.54 DRD2 DRD3
29 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.52 GHRL GHSR
30 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.51 DRD2 DRD3
31 positive regulation of multicellular organism growth GO:0040018 9.5 DRD2 GHRL GHSR
32 negative regulation of interleukin-6 biosynthetic process GO:0045409 9.49 GHRL GHSR
33 positive regulation of appetite GO:0032100 9.48 GHRL GHSR
34 negative regulation of dopamine receptor signaling pathway GO:0060160 9.43 DRD2 DRD3
35 acid secretion GO:0046717 9.4 DRD2 DRD3
36 response to histamine GO:0034776 9.37 DRD2 DRD3
37 negative regulation of blood pressure GO:0045776 9.33 DRD2 DRD3 NOS1
38 regulation of locomotion involved in locomotory behavior GO:0090325 9.26 DRD2 DRD3
39 G-protein coupled receptor signaling pathway GO:0007186 9.17 DRD2 DRD3 GAST GHRL GHSR MLN
40 negative regulation of insulin secretion GO:0046676 9.13 DRD2 GHRL GHSR

Molecular functions related to Gastroparesis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 9.43 CYP2D6 DRD2 DRD3
2 dopamine binding GO:0035240 9.37 DRD2 DRD3
3 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.32 DRD2 DRD3
4 dopamine neurotransmitter receptor activity GO:0004952 9.16 DRD2 DRD3
5 growth hormone-releasing hormone receptor activity GO:0016520 8.96 GHSR MLNR
6 hormone activity GO:0005179 8.92 CCK GAST GHRL MLN

Sources for Gastroparesis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....